Search Results - "Wolfe, Gil I"

Ocular myasthenia gravis – How effective is low dose prednisone long term? by Verma, Rashmi, Wolfe, Gil I., Kupersmith, Mark J.

“…Controversy persists on the best treatment to control ocular myasthenia gravis (OMG) and reduce conversion to generalized myasthenia gravis (GMG). We…”
Get full text

MG-ADL: Still a relevant outcome measure by Muppidi, Srikanth, Wolfe, Gil I., Conaway, Mark, Burns, Ted M.

“…Introduction: The aim of this analysis was to examine the performance of the Myasthenia Gravis–specific Activities of Daily Living scale (MG‐ADL) during a…”
Get full text

Serum metabolomics of treatment response in myasthenia gravis by Sikorski, Patricia, Li, Yaoxiang, Cheema, Mehar, Wolfe, Gil I, Kusner, Linda L, Aban, Inmaculada, Kaminski, Henry J

“…High-dose prednisone use, lasting several months or longer, is the primary initial therapy for myasthenia gravis (MG). Upwards of a third of patients do not…”
Get full text

Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial by Benatar, Michael, Mcdermott, Michael P., Sanders, Donald B., Wolfe, Gil I., Barohn, Richard J., Nowak, Richard J., Hehir, Michael, Juel, Vern, Katzberg, Hans, Tawil, Rabi

“…ABSTRACT Introduction: In this study we evaluated the safety, tolerability, and efficacy of prednisone in patients with ocular myasthenia gravis (OMG)…”
Get full text

Consensus treatment recommendations for late-onset Pompe disease by Cupler, Edward J., Berger, Kenneth I., Leshner, Robert T., Wolfe, Gil I., Han, Jay J., Barohn, Richard J., Kissel, John T.

“…Introduction: Pompe disease is a rare, autosomal recessive disorder caused by deficiency of the glycogen‐degrading lysosomal enzyme acid alpha‐glucosidase…”
Get full text

Clinical findings in MuSK-antibody positive myasthenia gravis: A U.S. experience by Pasnoor, Mamatha, Wolfe, Gil I., Nations, Sharon, Trivedi, Jaya, Barohn, Richard J., Herbelin, Laura, McVey, April, Dimachkie, Mazen, Kissel, John, Walsh, Ronan, Amato, Anthony, Mozaffar, Tahseen, Hungs, Marcel, Chui, Luis, Goldstein, Jonathan, Novella, Steven, Burns, Ted, Phillips, Lawrence, Claussen, Gwendolyn, Young, Angela, Bertorini, Tulio, Oh, Shin

“…We performed a retrospective chart review on 53 muscle‐specific kinase antibody (MuSK‐Ab)‐positive myasthenia gravis (MG) patients at nine university‐based…”
Get full text

Histopathology of thymectomy specimens from the MGTX-trial: Entropy analysis as strategy to quantify spatial heterogeneity of lymphoid follicle and fat distribution by Weis, Cleo-Aron, Aban, Inmaculada B, Cutter, Garry, Kaminski, Henry J, Scharff, Christoph, Grießmann, Benedict W, Deligianni, Maria, Kayser, Klaus, Wolfe, Gil I, Ströbel, Philipp, Marx, Alexander

“…The thymectomy specimens from the "thymectomy trial in non-thymomatous myasthenia gravis patients receiving prednisone therapy" (MGTX) underwent rigid and…”
Get full text

Primary lateral sclerosis by Singer, Mike A., Statland, Jeffrey M., Wolfe, Gil I., Barohn, Richard J.

“…The spectrum of motor neuron diseases ranges from disorders that clinically are limited to lower motor neurons to those that exclusively affect upper motor…”
Get full text

Comparative Clinical Outcomes of Thymectomy for Myasthenia Gravis Performed by Extended Transsternal and Minimally Invasive Approaches by Meyer, Dan M., MD, Herbert, Morley A., PhD, Sobhani, Nasin C, Tavakolian, Paul, Duncan, Andrea, RN, Bruns, Michelle, MLA, Korngut, Kevin, BS, Williams, Janet, BA, Prince, Syma L., RN, BSN, Huber, L., RN, BSN, Wolfe, Gil I., MD, Mack, Michael J., MD

“…Background Both transsternal and video-assisted thoracoscopic surgery (VATS) approaches are used for thymectomy in myasthenia gravis. We compared outcomes of…”
Get full text

Clinical Phenotype of Muscle-specific Tyrosine Kinase-antibody-positive Myasthenia Gravis by Wolfe, Gil I., Oh, Shin J.

“…Antibodies to muscle‐specific receptor tyrosine kinase (MuSK‐Ab) are detected in approximately 40% of generalized acetylcholine receptor (AChR)…”
Get full text

Cerebral Paragonimiasis: An Unusual Manifestation of a Rare Parasitic Infection by Kohli, Supriya, MD, Farooq, Osman, MD, Jani, Ronak B., MD, Wolfe, Gil I., MD

“…Abstract Background Paragonimiasis is a parasitic disease that typically produces a subacute to chronic inflammatory disease of the lung. Although rare in the…”
Get full text

Status of the Thymectomy Trial for Nonthymomatous Myasthenia Gravis Patients Receiving Prednisone by Newsom-Davis, John, Cutter, Gary, Wolfe, Gil I., Kaminski, Henry J., Jaretzki III, Alfred, Minisman, Greg, Aban, Inmaculada, Conwit, Robin

“…The primary study [MGTX] aims to answer three questions: does extended transsternal thymectomy combined with the prednisone protocol, when compared with the…”
Get full text

International consensus guidance for management of myasthenia gravis: Executive summary by Sanders, Donald B, Wolfe, Gil I, Benatar, Michael, Evoli, Amelia, Gilhus, Nils E, Illa, Isabel, Kuntz, Nancy, Massey, Janice M, Melms, Arthur, Murai, Hiroyuki, Nicolle, Michael, Palace, Jacqueline, Richman, David P, Verschuuren, Jan, Narayanaswami, Pushpa

“…OBJECTIVE:To develop formal consensus-based guidance for the management of myasthenia gravis (MG). METHODS:In October 2013, the Myasthenia Gravis Foundation of…”
Get full text

Static magnetic field therapy for symptomatic diabetic neuropathy: a randomized, double-blind, placebo-controlled trial by Weintraub, Michael I, Wolfe, Gil I, Barohn, Richard A, Cole, Steven P, Parry, Gareth J, Hayat, Ghazala, Cohen, Jeffrey A, Page, Jeffrey C, Bromberg, Mark B, Schwartz, Sherwyn L

“…Weintraub MI, Wolfe GI, Barohn RA, Cole SP, Parry GJ, Hayat G, Cohen JA, Page JC, Bromberg MB, Schwartz SL, and the Magnetic Research Group. Static magnetic…”
Get full text

IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis by Wolfe, Gil I., Ward, E. Sally, de Haard, Hans, Ulrichts, Peter, Mozaffar, Tahseen, Pasnoor, Mamatha, Vidarsson, Gestur

“…The neonatal Fc receptor (FcRn) is an MHC class I–like molecule that is widely distributed in mammalian organs, tissues, and cells. FcRn is critical to…”
Get full text

Psychometric properties of MG-ADL items and MG-ADL score: An assessment of distributional characteristics, validity and factor structure in two large datasets by Janssen, Mathieu F., Dewilde, Sarah, Wolfe, Gil I., Muppidi, Srikanth, Phillips, Glenn

“…The Myasthenia Gravis–Activities of Daily Living scale (MG-ADL) is an 8-item outcome measure to assess symptoms and functional limitations in myasthenia gravis…”
Get full text

Repetitive nerve stimulation of facial muscles in musk antibody-positive myasthenia gravis by Oh, Shin J., Hatanaka, Yuki, Hemmi, Shoji, Young, Angela M., Scheufele, Mia L., Nations, Sharon P., Lu, Liang, Claussen, Gwen C., Wolfe, Gil I.

“…To better define electrophysiological abnormalities in myasthenia gravis (MG) patients with muscle‐specific tyrosine kinase (MuSK) antibodies (Ab), we compared…”
Get full text

Treatment of Painful Peripheral Neuropathy by Trivedi, Jaya R., MD, Silvestri, Nicholas J., MD, Wolfe, Gil I., MD

“…Neuropathic pain management is an important aspect in the management of painful peripheral neuropathy. Anticonvulsants and antidepressants have been studied…”
Get full text

Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial by Howard, Jr, James F, Nowak, Richard J, Wolfe, Gil I, Freimer, Miriam L, Vu, Tuan H, Hinton, John L, Benatar, Michael, Duda, Petra W, MacDougall, James E, Farzaneh-Far, Ramin, Kaminski, Henry J, Barohn, Richard, Dimachkie, Mazen, Pasnoor, Mamatha, Farmakidis, Constantine, Liu, Tina, Colgan, Samantha, Benatar, Michael G, Bertorini, Tulio, Pillai, Rekha, Henegar, Robert, Bromberg, Mark, Gibson, Summer, Janecki, Teresa, Freimer, Miriam, Elsheikh, Bakri, Matisak, Paige, Genge, Angela, Guidon, Amanda, David, William, Habib, Ali A, Mathew, Veena, Mozaffar, Tahseen, Hewitt, William, Barnett, Deborah, Sullivan, Patricia, Ho, Doreen, Traub, Rebecca E, Chopra, Manisha, Aly, Radwa, Bayat, Elham, Abu-Rub, Mohammad, Khan, Shaida, Lange, Dale, Holzberg, Shara, Khatri, Bhupendra, Lindman, Emily, Olapo, Tayo, Sershon, Lisa M, Lisak, Robert P, Bernitsas, Evanthia, Jia, Kelly, Malik, Rabia, Lewis-Collins, Tiffany D, Nicolle, Michael, Sharma, Aditi, Roy, Bhaskar, Nye, Joan, Pulley, Michael, Berger, Alan, Shabbir, Yasmeen, Sachdev, Amit, Patterson, Kimberly, Siddiqi, Zaeem, Sivak, Mark, Bratton, Joan, Small, George, Kohli, Anem, Fetter, Mary, Vu, Tuan, Lam, Lucy, Harvey, Brittany, Silvestri, Nicholas, Patrick, Kara, Zakalik, Karen, MacDougall, James, Pontius, Angela, Hoarty, Michelle

“…Many patients with generalized myasthenia gravis (gMG) have substantial clinical disability, persistent disease burden, and adverse effects attributable to…”
Get more information

Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG? by Allen, Jeffrey A., Gelinas, Deborah F., Freimer, Miriam, Runken, M. Chris, Wolfe, Gil I.

“…Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired neurological disorder characterized clinically by weakness and impaired sensory…”
Get full text